Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formu...
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2024-02-06
- Target Recruit Count
- 58
- Registration Number
- NCT01979393
- Locations
- 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇫🇷Centre Leon Berard, Lyon, France
🇪🇸Hospital Universitario San Carlos, Madrid, Spain
Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT01961765
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT01954745
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- Edwin Posadas, MD
- Target Recruit Count
- 17
- Registration Number
- NCT01834651
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 32
- Registration Number
- NCT01761773
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT01755195
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Cabozantinib for Metastatic Triple Negative BrCa
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT01738438
- Locations
- 🇺🇸
Dana-Farber Cancer Institute at Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cabozantinib in Men With Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 9
- Registration Number
- NCT01703065
- Locations
- 🇺🇸
Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States
Cabozantinib for Advanced Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 69
- Registration Number
- NCT01688999
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 49
- Registration Number
- NCT01683994
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.